β-Adrenergic Blockers

Hypertension: A Companion to Brenner and Rector's The Kidney

Volumn , Issue , 2005, Pages 653-659

  Frishman, William H ^a,b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85135427547     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-0258-5.50153-8     Document Type: Chapter

References (45)

1. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). Express version: JAMA. Hypertension 2003, 42:1206-1252. Complete version:.
2. Frishman WH, Sonnenblick EH β-adrenergic blocking drugs and calcium channel blockers. Hurst's The Heart, 9th ed 1998, 1583-1618. McGraw Hill, New York. R.W. Alexander, R.C. Schlant, V. Fuster (Eds.).
3. Frishman WH, Bryzinski BS, Coulson LR, et al. A multifactorial trial design to assess combination therapy in hypertension: Treatment with bisoprolol and hydrochlorothiazide. Arch Intern Med 1994, 154:1461-1468.
4. Frishman WH Alpha and beta-adrenergic blocking drugs. Cardiovascular Pharmacotherapeutics, 2nd ed 2003, 67-97. McGraw Hill, New York. W.H. Frishman, E.H. Sonnenblick, D.A. Sica (Eds.).
5. Frishman WH Alpha and beta-adrenergic blocking drugs. Cardiovascular Pharmacotherapeutics Manual, 2nd ed 2004, 19-57. McGraw Hill, New York. W.H. Frishman, E.H. Sonnenblick, D.A. Sica (Eds.).
6. Frishman WH Clinical Pharmacology of the β-Adrenoceptor Blocking Drugs, 2nd ed 1984, Appleton-Century-Crofts, Norwalk.
7. Frishman WH, Alwarshetty M Beta-adrenergic blockers in systemic hypertension: Pharmacokinetic considerations related to the JNC-VI and WHO-ISH guidelines. Clin Pharmacokinet 2002, 41:505-516.
8. TM), a new chronotherapeutic formulation. Heart Dis 2003, 5:176-181.
9. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial. JAMA 2003, 289:2073-2082.
10. Frishman WH, Murthy VS, Strom JA, et al. Ultra short-acting β-adrenoreceptor blocking drug: Esmolol. Cardiovascular Drug Therapy, 2nd ed 1996, 507-516. WB Saunders, Philadelphia. F.H. Messerli (Ed.).
11. Systolic Hypertension in the Elderly Program Cooperative Research Group. Implications of the Systolic Hypertension in the Elderly Program. Hypertension 1993, 21:335-343.
12. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men: A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993, 328:914-921.
13. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: A systematic review and meta-analysis. JAMA 1997, 277:739-745.
14. ALLHAT Officers and Coordinators Major outcomes in high risk hypertensive patients randomized to angiotensin converting enzyme inhibitor therapy or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997.
15. Frishman WH, Sica DA β-Adrenergic blockers. Hypertension Primer, 3rd ed 2003, 417-421. American Heart Association, Dallas. J.L. Izzo, H.R. Black (Eds.).
16. Frishman WH Carvedilol. N Engl J Med 1998, 339:1759-1765.
17. Abrams J, Frishman WH, Bates SM, et al. Pharmacologic options for treatment of ischemic disease. Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease, 2nd ed 2002, 97-153. WB Saunders, Philadelphia. E.D. Antman (Ed.).
18. Fihn SD, Williams SV, Daley J, et al. Guidelines for the management of patients with chronic stable angina: Treatment. Ann Intern Med 2001, 135:616-632.
19. Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing β blockers, calcium antagonists and nitrates for stable angina. JAMA 1999, 281:1927-1936.
20. LeJemtel TH, Sonnenblick EH, Frishman WH Diagnosis and management of heart failure. Hurst's The Heart, 11th ed 2004, 723-762. McGraw Hill, New York. V. Fuster, R.W. Alexander, R.A. O'Rourke (Eds.).
21. Frishman WH, Cavusoglu E β-adrenergic blockers and their role in the therapy of arrhythmias. Cardiac Arrhythmias: Mechanisms, Diagnosis and Management 1995, 421-433. Williams & Wilkins, Baltimore. P.J. Podrid, P.R. Kowey (Eds.).
22. Frishman WH Postinfarction survival: Role of β-adrenergic blockade. Atherosclerosis and Coronary Artery Disease 1996, 1205-1214. Lippincott Raven, Philadelphia. V. Fuster, R. Ross, E.J. Topol (Eds.).
23. CAPRICORN Investigators Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: The CAPRICORN randomized trial. Lancet 2001, 357:1385-1390.
24. Qasqas SA, McPherson C, Frishman WH, Elkayam U Cardiovascular pharmacotherapeutic considerations during pregnancy and lactation. Parts 1 and 2. Cardiol Rev 2004, 12:201-221, 240-261.
25. Auerbach AD, Goldman L β blockers and reduction of cardiac events in noncardiac surgery. Clinical applications. JAMA 2002, 287:1445-1447.
26. Devereux RB Do antihypertensive drugs differ in their ability to regress left ventricular hypertrophy?. Circulation 1997, 95:1983-1985.
27. Dahlof B Left ventricular hypertrophy and angiotensin II antagonists. Am J Hypertens 2001, 14:174-182.
28. Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation 2003, 108:684-690.
29. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet 2002, 359:995-1003.
30. Messerli FH, Frossman E, Goldbourt U Are β blockers efficacious as first-line therapy for hypertension in the elderly?. JAMA 1998, 279:1903-1907.
31. Packer M, Fowler MB, Roecker EB, et al. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on morbidity of patients with severe chronic heart failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation 2002, 106:2194-2199.
32. Poole-Wilson PA, Swedberg K, Cleland JGF, et al. Carvedilol or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): Randomized controlled trial. Lancet 2003, 362(9377):7-13.
33. CIBIS II The Cardiac Insufficiency Bisoprolol Study II. A randomized trial. Lancet 1999, 353:9-13.
34. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effect of con-trolled-release metoprolol on total mortality, hospitalizations and well-being in patients with heart failure. The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000, 283:1295-1302.
35. Gress TW, Nieto J, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000, 342:905-912.
36. Sowers JR, Bakris GL Antihypertensive therapy and the risk of type 2 diabetes mellitus (editorial). N Engl J Med 2000, 342:969-970.
37. Schacter NS, Zimetbaum P, Frishman WH Lipid-lowering drugs. Cardiovascular Pharmacotherapeutics, 2nd ed 2003, 317-353. McGraw Hill, New York. W.H. Frishman, E.H. Sonnenblick, D.A. Sica (Eds.).
38. Frishman WH, Razin A, Swencionis C, et al. Beta-adrenoceptor blockade in anxiety states: A new approach to therapy. Update. Cardiovasc Rev (Classics of the Decade Series) 1992, 13:8-13.
39. Frishman WH Atenolol and timolol: Two new systemic adrenoceptor antagonists. N Engl J Med 1982, 306:1456-1462.
40. Frishman WH Nadolol. A new β adrenoceptor antagonist. N Engl J Med 1981, 305:678-684.
41. Wurzelman J, Frishman MW, Aronson M, et al. Neuropsychiatric effects of antihypertensive drugs in the old old. Cardiol Clin 1987, 5:689-699.
42. Perez-Stable EJ, Halliday R, Gardiner PS, et al. The effects of propranolol on cognitive function and quality of life: A randomized trial among patients with diastolic hypertension. Am J Med 2000, 108:359-365.
43. Frishman WH, Sica DA Calcium channel blockers. Cardiovascular Pharmacotherapeutics, 2nd ed 2003, 105-130. McGraw Hill, New York. W.H. Frishman, E.H. Sonnenblick, D.A. Sica (Eds.).
44. Opie LH Cardiovascular drug interactions. Cardiovascular Pharmacotherapeutics, 2nd ed 2003, 875-891. McGraw Hill, New York. W.H. Frishman, E.H. Sonnenblick, D.A. Sica (Eds.).
45. Frishman WH, Opie LH, Sica DA Adverse cardiovascular drug interactions and complications. Hurst's The Heart, 11th ed 2004, 2169-2188. McGraw Hill, New York. V. Fuster, R.W. Alexander, R.A. O'Rourke (Eds.).